Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,172 GBX | -0.60% | -0.85% | +14.72% |
10:04am | ASTRAZENECA : UBS reiterates its Sell rating | ZD |
14/05 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.72% | 239B | |
+31.36% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+10.13% | 210B | |
-7.12% | 200B | |
+8.12% | 167B | |
-1.42% | 161B | |
+1.46% | 124B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study